A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Prenatal phthalate exposure in relation to placental corticotropin releasing hormone (pCRH) in the CANDLE cohort
Context: Phthalates may disrupt maternal-fetal-placental endocrine pathways, affecting pregnancy outcomes and child development. Placental corticotropin releasing hormone (pCRH) is critical for healthy pregnancy and child development, but understudied as a target of endocrine disruption. Objective: To examine phthalate metabolite concentrations (as mixtures and individually) in relation to pCRH. Design: Secondary data analysis from a prospective cohort study. Setting: Prenatal clinics in Tennessee, USA. Patients: 1018 pregnant women (61.4% non-Hispanic Black, 32% non-Hispanic White, 6.6% other) participated in the CANDLE study and provided data. Inclusion criteria included: low-medical-risk singleton pregnancy, age 16–40, and gestational weeks 16–29. Intervention: None. Main outcome measures: Plasma pCRH at two visits (mean gestational ages 23.0 and 31.8 weeks) and change in pCRH between visits (ΔpCRH). Results: In weighted quantile sums (WQS) regression models, phthalate mixtures were associated with higher pCRH at Visit 1 (β = 0.07, 95 %CI: 0.02, 0.11) but lower pCRH at Visit 2 (β = −0.08, 95 %CI: −0.14, −0.02). In stratified analyses, among women with gestational diabetes (n = 59), phthalate mixtures were associated with lower pCRH at Visit 1 (β = −0.17, 95 %CI: −0.35, 0.0006) and Visit 2 (β = −0.35, 95 %CI: −0.50, −0.19), as well as greater ΔpCRH (β = 0.16, 95 %CI: 0.07, 0.25). Among women with gestational hypertension (n = 102), phthalate mixtures were associated with higher pCRH at Visit 1 (β = 0.20, 95 %CI: 0.03, 0.36) and Visit 2 (β = 0.42; 95 %CI: 0.19, 0.64) and lower ΔpCRH (β = −0.17, 95 %CI: −0.29, −0.06). Significant interactions between individual phthalate metabolites and pregnancy complications were observed. Conclusions: Phthalates may impact placental CRH secretion, with differing effects across pregnancy. Differences in results between women with and without gestational diabetes and gestational hypertension suggest a need for further research examining whether women with pregnancy complications may be more vulnerable to endocrine-disrupting effects of phthalates.
Prenatal phthalate exposure in relation to placental corticotropin releasing hormone (pCRH) in the CANDLE cohort
Context: Phthalates may disrupt maternal-fetal-placental endocrine pathways, affecting pregnancy outcomes and child development. Placental corticotropin releasing hormone (pCRH) is critical for healthy pregnancy and child development, but understudied as a target of endocrine disruption. Objective: To examine phthalate metabolite concentrations (as mixtures and individually) in relation to pCRH. Design: Secondary data analysis from a prospective cohort study. Setting: Prenatal clinics in Tennessee, USA. Patients: 1018 pregnant women (61.4% non-Hispanic Black, 32% non-Hispanic White, 6.6% other) participated in the CANDLE study and provided data. Inclusion criteria included: low-medical-risk singleton pregnancy, age 16–40, and gestational weeks 16–29. Intervention: None. Main outcome measures: Plasma pCRH at two visits (mean gestational ages 23.0 and 31.8 weeks) and change in pCRH between visits (ΔpCRH). Results: In weighted quantile sums (WQS) regression models, phthalate mixtures were associated with higher pCRH at Visit 1 (β = 0.07, 95 %CI: 0.02, 0.11) but lower pCRH at Visit 2 (β = −0.08, 95 %CI: −0.14, −0.02). In stratified analyses, among women with gestational diabetes (n = 59), phthalate mixtures were associated with lower pCRH at Visit 1 (β = −0.17, 95 %CI: −0.35, 0.0006) and Visit 2 (β = −0.35, 95 %CI: −0.50, −0.19), as well as greater ΔpCRH (β = 0.16, 95 %CI: 0.07, 0.25). Among women with gestational hypertension (n = 102), phthalate mixtures were associated with higher pCRH at Visit 1 (β = 0.20, 95 %CI: 0.03, 0.36) and Visit 2 (β = 0.42; 95 %CI: 0.19, 0.64) and lower ΔpCRH (β = −0.17, 95 %CI: −0.29, −0.06). Significant interactions between individual phthalate metabolites and pregnancy complications were observed. Conclusions: Phthalates may impact placental CRH secretion, with differing effects across pregnancy. Differences in results between women with and without gestational diabetes and gestational hypertension suggest a need for further research examining whether women with pregnancy complications may be more vulnerable to endocrine-disrupting effects of phthalates.
Prenatal phthalate exposure in relation to placental corticotropin releasing hormone (pCRH) in the CANDLE cohort
Emily S. Barrett (author) / Matthew Corsetti (author) / Drew Day (author) / Sally W. Thurston (author) / Christine T. Loftus (author) / Catherine J. Karr (author) / Kurunthachalam Kannan (author) / Kaja Z. LeWinn (author) / Alicia K. Smith (author) / Roger Smith (author)
2022
Article (Journal)
Electronic Resource
Unknown
Metadata by DOAJ is licensed under CC BY-SA 1.0
Characterising corticotropin releasing hormone receptor-induced signalling dynamics
| British Library Conference Proceedings | 2009
A combined cohort analysis of prenatal exposure to phthalate mixtures and childhood asthma
| DOAJ | 2020